• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Magic bullets hit the target
3. Advances in monoclonal antibody therapy
4. Antibodies for cancer immunotherapy
5. T-cell leukemia/lymphoma - an orphan disease
6. Targets for receptor-directed therapy
7. The IL-2 receptor
8. 3 cytokine binding membrane components
9. Shared chains
10. Distribution of IL-2 receptors
11. Soluble IL-2R-alpha in pateints with ATL
12. Candidates for IL-2 receptor-directed therapy
13. Allograft protocols
14. Soluble IL-2R levels in autoimmune diseases
15. Adult T cell leukemia/lymphoma
16. IL-2 receptor expression in ATL
17. Murine model of ATL
18. Leukemia treatment with various antibodies
19. Effect of HAT: FcR intact vs. FcR knockout mice
20. Materials to eliminate IL-2R alpha expressing cells
21. IL-2R alpha as a target for immunotherapy of ATL
22. Daclizumab (humanized anti-Tac)
23. Anti-Tac therapy of ATL
24. Remission after IL-2R-alpha-directed therapy
25. Daclizumab therapy of patients with MS
26. Changes in CE lesions during daclizumab therapy
27. Daclizumab can decrease renal allograft rejection
28. Anti-tumor effect enhanced by combination therapy
29. Arming of cytokines with toxins or radionuclides
30. Effect of flavopiridol and HAT in an ATL model
31. Anti-Tac(Fv)-PE38 (LMB2)
32. Response of HCL to LMB2
33. Issues for effective radioimmunotherapy
34. Alpha/beta emitters in radioimmunotherapy
35. Materials to eliminate IL-2R alpha expressing cells
36. Radioimmunotherapy of ATL with 90Y-anti-Tac
37. 90Y-anti-Tac effective therapy for ATL
38. 111In anti-Tac
39. Limitations of intact antibodies
40. Pretargeting approach
41. Biodistribution of In-11-HAT in nude mice
42. Biodistribution of pretargeted In-DOTA-biotin
43. Effects of 213Bi anti-Tac/SA pretarget therapy
44. Survival (fusion protein, Y-90, SUDHL-1)
45. Discovery of IL-15
46. The structure of human IL-15
47. IL-15 vs. IL-2 cytokine interaction
48. IL-2/15 roles in the life and death of lymphocytes
49. Control of IL-15 expression
50. Abnormalities of IL-15 expression
51. The role of IL-15 in celiac disease
52. HAT inhibita IL-2 ; Mik beta1 inhibits IL-15
53. Humanized Mik beta1 prolongs allograft survival
54. Immunoregulatory negative checkpoint blockade
55. CD4+ CD25+ negative regulatory Tregs
56. mAb PC61 facilitates tumor rejection
57. IL-15 induced STAT-mediated gene regulation
58. Strategies to interfere with cytokine signaling
59. Summary
60. Concluding remarks

Topics Covered

• Structure and function of IL-2 receptor
• Disorders of IL-2 receptor expression in disease
• IL-2R alpha-directed monoclonal antibody mediated therapy of leukemia and autoimmune diseases
• Anti-IL-2E alpha monoclonals armed with toxins or radionuclides
• IL-15 and its use of the IL-/IL-15 beta receptor
• IL-2/IL-15 R beta receptor directed therapy for leukemia and autoimmune diseases
• The IL-2R alpha as a target in the elimination of CD4+ CD25+ T-regs (suppressor cells)

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Cancer
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Oncology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on June 13, 2019

Financial Disclosures

• Prof. Thomas Waldmann has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.